Depression sum-scores don't add up: why analyzing specific depression symptoms is essential by Fried, Eiko I. (Author) et al.
$VSSFOU$POUSPWFSTJFTJO1TZDIJBUSZ
Fried and Nesse BMC Medicine  (2015) 13:72 
DOI 10.1186/s12916-015-0325-4REVIEW Open AccessDepression sum-scores don’t add up: why
analyzing specific depression symptoms is
essential
Eiko I Fried1* and Randolph M Nesse2Abstract
Most measures of depression severity are based on the number of reported symptoms, and threshold scores are often
used to classify individuals as healthy or depressed. This method – and research results based on it – are valid if
depression is a single condition, and all symptoms are equally good severity indicators. Here, we review a host of studies
documenting that specific depressive symptoms like sad mood, insomnia, concentration problems, and suicidal ideation
are distinct phenomena that differ from each other in important dimensions such as underlying biology, impact on
impairment, and risk factors. Furthermore, specific life events predict increases in particular depression symptoms, and
there is evidence for direct causal links among symptoms. We suggest that the pervasive use of sum-scores to estimate
depression severity has obfuscated crucial insights and contributed to the lack of progress in key research areas such
as identifying biomarkers and more efficacious antidepressants. The analysis of individual symptoms and their causal
associations offers a way forward. We offer specific suggestions with practical implications for future research.
Keywords: Depression symptoms, Diagnostic and Statistical Manual of Mental Disorders, Heterogeneity, Major
depressive disorder, NosologyBackground
“At present major depression has become a monolith,
with the assumption that the diagnosis can be made
merely on the number of depressive symptoms present
[…]. It may be politically important to utter such
simplifications to doctors in general medical settings,
but it is a convenient fiction.”
– Goldberg, 2011, p. 227 [1]
Major depressive disorder (MDD) is one of the most
common psychiatric disorders, with an estimated lifetime
prevalence rate in the USA of 16.2% [2]. It is the leading
cause of disability worldwide, and one of the top three
causes of disease burden worldwide [3]. About 60% of
individuals meeting criteria for MDD, as defined by the
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unless otherwise stated.(DSM-5) [4], report severe or very severe impairment of
functioning [2] that highly compromises the capacity for
self-care and independent living.
The severity of MDD is routinely estimated by adding
up severity scores for many disparate symptoms to create
a sum-score, and threshold values for these sum-scores
are commonly used to classify individuals as depressed or
not depressed. This practice of constructing sum-scores
and collapsing individuals with different symptoms into
one undifferentiated category is based on the assumption
that depression is a single condition, and that all symptoms
are interchangeable and equally good indicators. This
review shows that this common practice discards much
critical information about individual symptoms whose
analysis can provide important insights.Depression heterogeneity
In the DSM-5, MDD is characterized by nine symptoms:
1. depressed mood; 2. markedly diminished interest or
pleasure; 3. increase or decrease in either weight or
appetite; 4. insomnia or hypersomnia; 5. psychomotor
agitation or retardation; 6. fatigue or loss of energy;tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fried and Nesse BMC Medicine  (2015) 13:72 Page 2 of 117. feelings of worthlessness or inappropriate guilt; 8. dimin-
ished ability to think or concentrate, or indecisiveness; and
9. recurrent thoughts of death or recurrent suicidal idea-
tion. To qualify for the diagnosis, an individual must exhibit
five or more symptoms, one of which must be either
depressed mood or anhedonia. Of note, all symptoms
except the first contain sub-symptoms (e.g., diminished
interest or pleasure). Moreover, three symptoms – sleep
problems, weight/appetite problems, and psychomotor
problems – encompass opposite features (insomnia vs.
hypersomnia; weight/appetite gain vs. loss; psychomotor
retardation vs. agitation). This leads to roughly 1,000
unique combinations of symptoms that all qualify for
a diagnosis of MDD, some of which do not share a
single symptom [5]. It is not surprising that symptom
variability among individuals diagnosed with MDD is
well-established [5-7].
Cutoff values based on sum-scores from rating scales
such as the Beck Depression Inventory (BDI) [8] or the
Hamilton Rating Scale for Depression (HRSD) [9] are
routinely used as the main criterion to enroll participants
in research studies. While the DSM has a hierarchical
structure that features two core symptoms, and while
symptoms have to cause significant distress or impairment
in important areas of functioning for a diagnosis, these
criteria are not accounted for in such scales, further
increasing the heterogeneity of depressed samples [5].
The next section reviews evidence underlining the
importance of attending to particular depression
symptoms. We then describe how the use of sum-scores
obfuscates important insights in various domains, and
suggest that this may help to explain slow progress in key
research areas, such as identifying biomarkers and
more efficacious antidepressants. We conclude the review
with a list of suggestions that have practical research
implications.
Review of symptom-based depression research
Extensive research has described individual depression
symptoms; however, the significance of individual symptoms
has not been systematically reviewed previously. Here, we
describe how attending to specific symptoms has led to
insights in research on biomarkers, antidepressant efficacy,
depression risk factors, impaired psychological functioning,
and causal effects among particular depression symptoms.
Symptom specificity in biomarker research
Despite extraordinary research expenditures and large
genome-wide association studies, no pathognomonic
biological markers of depression have been identified.
This has been a major disappointment. In 1980, the
DSM-III [10] preamble predicted that biomarkers
associated with most diagnoses would be identified by
the time the DSM-IV [11] appeared; 35 years and twoDSM versions later, and with the exception of some
neurological disorders, not one biological test for mental
disorders was ready for inclusion in the criteria sets for
the DSM-5, and not a single psychiatric diagnosis can be
validated by laboratory or imaging biomarkers [12].
For depression research, results are specifically dis-
appointing. In a recent large genome-wide association
study with 34,549 subjects, no single locus reached
genome-wide significance [13]. This is consistent with
numerous other large genetic studies that have failed
to identify any confirmed associations for MDD [14-17].
Studies predicting antidepressant response by com-
mon genetic variants have led to similarly disappointing
results [18].
The analysis of specific symptoms offers opportunities
to investigate biological factors that may be related to
specific syndromes. Jang et al. [19] showed that 14
depression symptoms differ from each other in their
degree of heritability (h2 range, 0–35%). Somatic
symptoms such as loss of appetite and loss of libido,
as well as cognitions such as guilt or hopelessness
(possibly reflecting heritable personality traits), showed
higher heritability coefficients than other symptoms like
negative affect or tearfulness. Another study [20] revealed
differential associations of symptoms with specific
genetic polymorphisms; for example, the symptom
‘middle insomnia’ assessed by the HRSD was correlated
with the GGCCGGGC haplotype in the first haplotype
block of TPH1. In addition, a recent report of 7,500 twins
identified three genetic factors that exhibited pronounced
differential associations with specific MDD symptoms
[21]; the authors concluded that the “DSM-IV syndrome
of MD[D] does not reflect a single dimension of genetic
liability” (p. 599). Guintivano and Brown [22] analyzed
several independent samples of post-mortem brains and
blood samples from living subjects to document that
80% of the variation in one of the most relevant specific
symptoms, suicidal behavior, could be explained by how
polymorphisms of the gene SKA2 interacted with anxiety
and stress.
Moving away from genes and gene expression to hormones,
the hypothesis that depression can be caused by inflammation
has received considerable attention in recent years [23,24].
However, evidence shows that less than half of the individuals
diagnosed with depression exhibit elevated inflammatory
markers [25], and elevated levels of cytokines are neither
highly sensitive nor specific to MDD [26]. Furthermore,
somatic symptoms such as sleep problems, appetite gain,
and weight gain seem elevated in the context of inflam-
mation [27-29], suggesting symptom specificity. A recent
review acknowledges intragroup variability of MDD
as main limitation of the research on inflammation and
depression [26], and suggests that future analyses of
distinct endophenotypes may move the field forward.
Table 1 Depression symptoms and common
antidepressant side effects
Symptoms prevalent among
depressed patients
DSM-5 criterion
symptoms
Antidepressant
side effects
Depressed mood + –
Anhedonia + –
Feelings of worthlessness + –
Appetite/weight problems + +
Sleep problems + +
Psychomotor problems + +
Fatigue + +
Concentration problems + +
Suicidal ideation + +
Anxiety – +
Sexual dysfunction – +
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their biological correlates. This underlines the heteroge-
neous nature of depression, which may in turn explain the
lack of progress in validating depression diagnosis
with biomarkers. Analyzing associations between symptom
sum-scores and genetic markers can only capture the
shared genetic variance of all symptoms, which may be
low. A symptom-based approach offers opportunities for
future research that could provide a potential partial
explanation for the “mystery of missing heritability” [30] –
the conundrum that specific genetic markers explain only
small proportions of the variance even for mental disorders
that are highly heritable. Specific markers may correlate
better with specific symptoms independent of diagnostic
categories – genes do not read the DSM [31]. Studies on
symptom-polymorphism associations instead of syndrome-
polymorphism associations, similar to the one conducted
by Myung et al. [20], may prove insightful.
The impact of antidepressants on specific symptoms
Several large meta-analyses of clinical trials have demon-
strated that antidepressants outperform placebos in less
than half of the trials, and that clinically relevant improve-
ments can be documented only for a minority of severely
depressed patients [32-34]. Part of the difficulty may be that
measuring antidepressant efficacy via sum-scores conceals
important effects on specific symptoms [35]. Little research
has been conducted on the effect of antidepressants on
individual depression symptoms compared to the mountain
of literature on specific side effects.
Significant side effects for both tricyclic antidepres-
sants and selective serotonin reuptake inhibitors have
prevalence rates of up to 27% in clinical trials [36,37],
and common side effects include insomnia, hypersomnia,
nervousness, anxiety, agitation, tremor, restlessness,
fatigue, somnolence, weight gain or weight loss, increased
or decreased appetite, hypertension, sexual dysfunction,
dry mouth, constipation, blurred vision, and sweating
[38,39] (Table 1). Side effects vary across drugs, and
some have more benign effects in specific domains.
For instance, certain atypical antidepressants have a
superior sexual side effect profile [40], and individuals
treated with bupropion and nortriptyline show decreased
rates of weight gain [41].
Curiously, some of the common side effects reported by
patients are the very symptoms that are used to measure
depression (Table 1). This means that reductions in
sum-scores thanks to reduced depression are concealed
by increases in sum-scores caused by drug side effects. In
addition, the instrument most commonly used in clinical
trials is the HRSD which, compared to other depression
scales such as the BDI, abounds in somatic symptoms that
resemble the side effect profile caused by antidepressant
treatment [42].The presence of particular symptoms has been used to
predict treatment response. Sleep problems, for instance,
reduce the efficacy of depression treatment [43]; patients
with persistent insomnia are more than twice as likely
to remain depressed [44], and insomnia can become
chronic despite successful resolution of depressive symp-
toms [45]. Other symptoms also moderate treatment effi-
cacy: anxiety symptoms reduce depression remission
rates, successful anxiety treatment prolongs depression
remission [46-48], and loss of interest, diminished activity,
and inability to make decisions predict poorer antidepres-
sant response [49].
The overlap of antidepressant side effects and depression
symptoms provides a compelling reason for analyzing
symptoms such as weight problems, sleep problems, or
sexual dysfunction separately from sum-scores. A detailed
analysis of how different antidepressants influence
specific symptoms may improve our ability to determine
antidepressant efficacy.
Risk factor heterogeneity
Risk factors identified for depression include previous
episodes of depression [50], demographic variables
such as age and sex [51,52], and personality traits such
as neuroticism [53]. Statistical models use these and
other risk factors to predict the presence or absence
of depression.
However, risk factors differ for different symptoms as first
demonstrated by Lux and Kendler [54], who analyzed the
associations of 25 risk factors on 9 different symptoms in a
cross-sectional study of 1,015 individuals. The influence of
risk factors differed substantially for different symptoms in
a pattern the authors found difficult to reconcile with the
general practice of summing symptoms. In another large
prospective study, risk factors for depression in medical
residents showed strong differential impact on changes of
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a sum-score suggested that women are at greater risk
to develop depression during residency, but analyzing
individual symptoms revealed that male residents were
more likely to experience elevated levels of suicidal
ideation under stress, whereas female study participants
were more prone to develop increases in sleep, appetite,
and concentration problems as well as fatigue.
Adverse life events are well-established risk factors for
depression [56], and the depression symptoms individuals
experience after a life event seem to depend on the nature
of the event. In one experimental study, as well as different
cross-sectional and longitudinal investigations of college
students and adult samples [57-61], specific types of life
events were associated with distinct patterns of depressive
symptoms. For instance, after a romantic breakup, individ-
uals mainly experienced depressed mood and feelings of
guilt, whereas chronic stress was associated with fatigue
and hypersomnia [59].
Overall, risk factors differ substantially for different
depressive symptoms, and sum-scores obscure such
insights. Studying the etiology of specific depression
symptoms may enable the development of personal-
ized prevention that focuses on specific problems and
symptoms before they transition into a full-fledged
depressive episode.MDD symptoms differentially impact on functioning
Most depressed individuals suffer from severe functional
impairment in various domains of living such as home life,
workplace, or family [2,62]. Their impairment is often long-
lasting and equal to that caused by other chronic medical
conditions such as diabetes or congestive heart failure
[63,64]. The question of whether individual depression
symptoms differentially impair psychosocial functioning is
thus of great importance.
In a study of 3,703 depressed outpatients, DSM-5 cri-
terion symptoms varied substantially in their associa-
tions with impairment [65]. Sad mood explained 20.9%
of the explained variance of impaired functioning, but
hypersomnia only contributed 0.9%. Symptoms also dif-
fered in their impacts across impairment subdomains.
For example, interest loss had high impact on social
activities, whereas fatigue most severely impacted home
management. The overall findings are consistent with
an earlier study documenting differential impact of DSM-
III criterion symptoms of depression on functioning [66].
While these results require replication in different
samples, they offer further evidence for the value of
considering depression symptoms separately. Not all
symptoms contribute equally to severity ratings, and
two individuals with similar sum-scores may suffer from
dramatically different levels of impairment.Causal associations among symptoms
Measuring depression severity by sum-scores of symptoms
ignores a plethora of information pertaining to the intra-
individual development of depression, including the power
of individual symptoms to cause other symptoms.
Insomnia, for example, leads to psychomotor impairment
[67], cognitive impairment [68], fatigue [69], low mood
[70], and suicidal ideation or actual suicide [71] –
symptoms that closely resemble DSM symptomatic
criteria for depression (psychomotor problems; fatigue;
diminished ability to think or concentrate, or indecisiveness;
suicidal ideation). A meta-analysis of laboratory-based sleep
loss studies documented the strength of these effects:
sleep-deprived subjects performed 0.87 standard deviations
(SD) lower than the control group on psychomotor tasks,
1.55 SD lower on cognitive tasks, and reported mood 3.16
SD lower than the control group. Collapsing over all three
measures, performance of sleep-deprived subjects at the
50th percentile in their group was equivalent to subjects at
the 9th percentile in the control group [72]. Another recent
meta-analysis revealed that psychiatric patients with sleep
disturbances are about twice as likely to report suicidal
behaviors compared to patients without sleep problems,
a finding that generalized across various conditions
including MDD, post-traumatic stress disorder (PTSD),
and schizophrenia [73].
Hopelessness describes negative expectancies about
the future [74]. Although not part of the DSM-5 MDD
criteria, it plays a major role in the cognitive triad
originally described by Beck [75], performs more strongly
than some DSM symptoms in distinguishing depressed
from healthy individuals [76], and is assessed in various
scales. Numerous studies have confirmed the predictive
role of hopelessness for suicidal ideation and suicide [71].
The effects are long-reaching: hopelessness predicted
suicidal thoughts, attempts, and actual suicide up to
13 years into the future in a large community sample [77],
and was identified as a predictor of suicide among
psychiatric patients followed for up to 20 years [78].
The association of hopelessness and suicide generalizes
from depressed individuals to patients with other
psychiatric conditions [79,80], once more underlining
symptom specificity irrespective of a given diagnosis.
Hopelessness predicts suicide better than the sum-score
from an inventory assessing multiple depressive symptoms
[80], and mediates the effect of rumination on suicidal
ideation and other depressive symptoms in children and
undergraduates [81,82]. In adolescents, rumination pre-
dicts the development of subsequent symptoms of depres-
sion, bulimia, and substance abuse, while depression and
bulimia symptoms in turn predict increases in rumination
[82,83]. Symptoms are associated in complex dynamic
networks that can form vicious circles which transcend
any specific diagnosis, a notion that is also supported by
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complex interactions among symptoms [84,85].
In contrast to longitudinal studies that span months or
years, experience sampling methods that allow for the
analysis of a large number of timepoints over a comparably
short timeframe have consistently revealed short-term
associations among depression symptoms (for a review, see
[86]). For example, sleep quality predicted affect during the
next day in a sample of 621 women, while daytime affect
was not related to subsequent night-time sleep quality [70],
implying a clear direction of causation. Complementing
such group-level analyses with longitudinal idiographic
studies is likely to contribute important information.
Bringmann et al. [87] documented differences among
depressed patients in the way their emotions impacted
each other across time; for instance, they found the auto-
regressive coefficient of rumination to vary substantially
across participants – rumination at a given timepoint
strongly predicted rumination at the next timepoint for
some individuals but not for others. Another study identi-
fied heterogeneity in the direction of causation between
depression symptoms and physical activity [88]. Overall, a
growing chorus of voices advocates the study of inter-
individual differences [89-91] which may pave the way
towards the development of more personalized treatment
approaches. Heterogeneity may also help to resolve
controversies about how some symptoms cause others.
Sleep deprivation, for instance, has rapid mood-enhancing
effects in some depressed patients [92], but other reports
suggest that sleep difficulties cause low mood [70].
The notion that symptoms trigger, influence, or maintain
other symptoms is widely recognized in clinical practice. A
major goal in cognitive therapy is trying to break
causal links between different MDD symptoms [75]
and approaches like mindfulness-based cognitive therapy
suggest that stopping rumination prevents it from causing
other depression symptoms [93]. Kim and Ahn [94]
demonstrated that causally central depression symptoms
(symptoms that trigger many other symptoms) are judged
to be more typical symptoms of depression by clinicians,
are recalled with greater accuracy than peripheral
symptoms, and are more likely to result in an MDD
diagnosis. The authors concluded that clinicians think
about causal networks of symptoms in ways far more
sophisticated than the atheoretical DSM approach of
counting symptoms.
Psychometric evidence
Psychometric techniques such as factor analysis (grouping
symptoms) and latent class analysis (grouping individuals)
are commonly used to address heterogeneity of MDD. In
a more detailed discussion of these methods we draw two
general conclusions, both of which support the study of
individual symptoms [5].First, extensive efforts to identify specific forms of treat-
ment effective for specific depression subtypes have been
disappointing. There has been little agreement about the
number and nature of depression subtypes [95-98], and
limited success in identifying external validators for sub-
types [99-102]. A recent systematic review that compared
the results of 34 factor and latent class analyses concluded
that they did not provide evidence for valid subtypes of
MDD [95], suggesting the analysis of individual symptoms.
Second, most rating scales for depression are multifac-
torial and do not measure one underlying factor [103-105].
However, individual symptoms are often at least
moderately inter-correlated [106], and the first factor –
often a general mood factor or higher-order factor –
explains substantially more variance than subsequent
factors [103,107]. This means that sum-scores certainly
carry information about the general psychopathological
load of a particular person, but that the approximation
may be fairly rough and that summing symptoms may
ignore important information [5,108] (for instance,
because MDD symptoms are differentially impairing
[65] and because sum-scores do not take into account
reciprocal interactions of symptoms [108]).
Applying psychometric tools such as item response
theory (IRT) and structural equation modeling (SEM)
can yield important insights on the level of individual
symptoms because they allow the examination of exact
relationships between symptoms and underlying dimen-
sions. One example technique that helps to understand
such relations is differential item functioning; a prior
study testing for this revealed that different MDD risk
factors, such as neuroticism or adverse life events,
impact on specific depression symptoms, implying that
symptoms are ‘biased’ towards certain risk factors [55].
A second practical application is research on residual
dependencies. A major assumption of IRT and SEM
models is that the underlying latent variables fully explain
the correlation of the manifest indicators. This is rarely
the case [109], and especially unlikely in the context of
MDD, seeing that symptoms influence each other directly
[86,110]. Ignoring such residual dependencies unaccounted
for by the latent variables, however, can substantially bias
inferences [109,111].
Practical research implications
Few would defend the notion that depression is a
homogeneous, discrete disease. Nonetheless, research
on depression generally assigns individuals with diverse
symptoms to the same disease category, and the search
for potential causes then proceeds as if depression is a
distinct disease entity, similar to measles or tuberculosis.
This could help to explain the inability to find biomarkers
or other external variables that can validate the diagnosis
of depression [112-116].
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problem. Because depression symptoms are understood
as interchangeable indicators of MDD, they are counted
instead of being analyzed [54,109]. As we have shown
above, however, symptoms are not equivalent, and sum-
scores add apples and oranges. As a result, two individuals
with equal sum-scores may have clinical conditions
whose severities differ drastically. This does not deny
the possibility that a central mechanism may switch
on multiple aspects of depression in some depressed
individuals; that obviously occurs, for instance, as a
result of interferon treatment that can cause anhedonia,
concentration problems, fatigue, and sleep problems [117].
The analysis of individual symptoms is nonetheless likely
to reveal patterns that are currently neglected.
We conclude with a list of practical symptom-based
implications that could advance depression research:
i) Analyze each symptom separately
ii) Assess non-DSM symptoms
iii) Distinguish between sub-symptoms
iv) Measure symptoms more objectively
v) Assess symptoms across diagnoses
vi) Improve reliability of assessment
vii) Use multiple scales to assess symptoms
viii) Investigate networks of symptom interactions
ix) Investigate symptom profiles in clinical trials
Improved measurement of MDD symptoms
The first group of research implications is for the
measurement of depression symptoms. After reviewing
many depression rating scales, Snaith [42] concluded that
“The measurement of ‘depression’ is as confused as the
basic construct of the state itself” (p. 296). Below we explain
why this is the case, and suggest several important steps
that could reduce confusion.
Assessment of important non-DSM symptoms
First, expanding the range of symptoms analyzed may
offer new insights. Today’s DSM MDD criterion symptoms
were determined largely by clinical consensus instead of
empirical evidence – one of the first proposed sets of symp-
toms goes back to the 1957 report by Cassidy [118], who
described clinical features of manic-depressive disorders.
The list was reworked later by Feighner [119], without
published data to support the changes. Today’s criterion
symptoms for MDD closely resemble the ones proposed
over 40 years ago, and numerous critical calls for a psycho-
metric (re)evaluation of depression and its symptoms have
had little impact (e.g., [54,76,120]). Anxiety and anger are
especially interesting symptoms for depression research;
both are highly prevalent in depressed patients and associ-
ated with worse clinical outcomes [46,121]. In a large
clinical trial, over half of the depressed patients reportedsignificant levels of anxiety, and remission of depression
was less likely and also took longer in this group [46].
Elevated baseline anxiety levels in treatment studies predict
higher depression levels later on [122], and anxiety was
identified as a risk symptom for adverse mental health
trajectories in a large epidemiological study [123]. Anger
is also prevalent among depressed patients, and has been
identified as a clinical marker of a more severe, chronic,
and complex depression [121]. The recently published
Symptoms of Depression Questionnaire includes a variety
of non-DSM symptoms, such as anger and anxiety, and
may prove an important tool for future research [124].
Distinguishing between sub-symptoms
Making more detailed assessments of compound symptoms
offers additional opportunities. Insomnia and hypersomnia
are opposites; subsuming them into ‘sleep problems’
hampers progress. A recent meta-analysis revealed that the
specific sleep problems of insomnia, parasomnia, and
sleep-related breathing disorders, but not hypersomnia
were related to suicidal behavior across a broad range
of psychiatric conditions such as MDD, PTSD, and
schizophrenia. Nightmares could also be included in
future depression questionnaires, seeing that individuals
suffering from nightmares showed a drastically elevated
risk for suicidality [125]. Psychomotor problems pose yet
another example, the impact of psychomotor retardation on
impairment of psychosocial functioning in the Sequenced
Alternatives to Relieve Depression (STAR*D) study was four
times greater than the impact of psychomotor agitation
[65]. Fatigue and sleepiness also need differentiation. As
Ferentinos et al. [69] point out, “insomnia causes fatigue,
while sleep apnea and narcolepsy cause mostly daytime
sleepiness; fatigue is alleviated by rest, while sleepiness is
relieved by sleep […]. Unfortunately, however, fatigue and
sleepiness may sometimes be confounded in clinical practice,
research, and psychometry” (p. 38).
Precise measurement of symptoms
The assessment of symptoms with higher precision offers
further opportunities. More complex constructs, such as
sadness, could be assessed with more than one question.
Self-report information can be augmented with objective
data. Patient reports about sleep quality can be comple-
mented by physiological data on sleep patterns and sleep
duration. Diaries can track sleep quality and weight
changes, and impaired concentration can be measured
using tests such as the d2 Test of Attention [126].
Transdiagnostic assessment of symptoms
Many symptoms are present in multiple disorders.
Mental disorders, such as MDD, PTSD, or generalized
anxiety disorder, are highly comorbid [127] in part
because they share defining symptoms such as sleep
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conditions. Fatigue is a diagnostic criterion for several
DSM disorders, but it also arises from many other medical
conditions in ways that can artificially increase depression
rates in such populations [128]. These symptoms may
thus not be particularly useful for determining the
presence of depression. However, the transdiagnostic
study of common psychopathological symptoms – e.g.,
the similarities and differences of fatigue across different
conditions – may offer substantial insights.
This idea also has implications for semi-structured
interviews, such as the Structural Clinical Interview for
DSM Disorders (SCID). In contrast to most scales, these
instruments offer the opportunity to assess a large amount
of symptoms from different diagnoses. However, it is
currently impossible to utilize data gathered via semi-
structured interviews for symptom-based research due to
the skip questions. Skip questions are a heuristic to save
time both for the interviewer and the interviewee: if an
individual reports none of the core symptoms necessary
for a diagnosis (such as anhedonia and sad mood for
MDD), all other symptoms are skipped. While this speeds
assessments, it loses vast amounts of information about
specific symptoms. Researchers employing the SCID and
similar instruments who query study participants about all
symptoms even in the absence of core symptoms will
generate important new findings.
Reliability of symptom measurement
One of the main challenges for symptom-based research is
reliably measuring symptoms. Common rating scales were
often not designed or validated for using symptom-level
information. Instead, the assessment of symptoms was
meant as measurement for an underlying disease [109].
This is an advantage of sum-scores: they include a number
of at least moderately correlated symptoms, and are thus
less susceptible to this measurement problem.
A possible solution to increase the reliability of symptom
assessment for self-report questionnaires or clinical inter-
views is to follow the general psychometric practice of
assessing variables of interest with more than one item. A
good example is the Inventory of Depression and Anxiety
Symptoms that uses multiple questions per symptom
domain. For instance, suicidal tendencies are measured via
6 different items [129], allowing for a more reliable
measurement. If this became standard practice, it would
likely reduce measurement error on the symptom level.
Use of multiple depression scales
Finally, for studies that must rely on symptom sum-scores,
different depression instruments should be utilized simul-
taneously, and conclusions should be considered robust
only if they generalize across different scales. Despite their
aim to measure the same underlying construct, there aremarked differences between different instruments for
measuring depression. For instance, scales differ in
how they classify depressed patients into severity
groups, so the scale chosen for a particular study can
bias who qualifies for enrollment, and who achieves
remission [130]. Instruments also include a variety of
different symptoms, and their sum-scores are often
only moderately correlated, suggesting that results
may often be idiosyncratic to the particular scale used
in a study [42,103,104,131]. In a review of 280 different
depression scales, Santor et al. [131] concluded that most
research is based on just a few scales, such as the HRSD
and BDI, so much of what we know about depression
depends on the quality of these scales. This is bad news,
considering the low psychometric quality of the HRSD
and BDI (poor inter-rater reliability, poor re-test reliability,
poor content validity, and poor psychometric performance
of certain items) [104,105]. While some changes were
made to the DSM criteria in the last decades, most rating
scales used today are at least 20 years old (in the case of
the HRSD, half a century) and do not reflect these changes;
most do not even include all nine DSM-5 criterion
symptoms [103].
Network models
While the more traditional SEM and IRT models assume
that all depression symptoms share a common cause
and are locally independent (i.e., uncorrelated beyond
the common cause; see [109]), a growing number of
studies have shown that symptoms can trigger other
symptoms. A recently developed framework – the network
approach to psychopathology – allows the study of
such dynamic interactions. Network models estimate
the relationships among symptoms within or across
time [106,109,110], and offer a new perspective on why
symptoms cluster. While latent variable models explain
symptom covariation by a latent factor that is viewed as
the common cause of all symptoms, network models
suggest that syndromes are constituted by the connections
among symptoms. This perspective encourages con-
sideration of how vicious circles of symptoms can fuel
each other, an alternative to the schema in which all
symptoms arise from a single brain disorder.
Reporting of symptom profiles
We anticipate fundamental advances from researchers
who report and analyze information about specific
symptoms. For instance, inconsistent reports about the
efficacy of antidepressants may result from samples with
different symptom patterns that may respond differently
to different agents. A meta-analysis to test this hypothesis
requires data on individual symptoms that is not avail-
able in the Food and Drug Administration database of
depression studies.
Fried and Nesse BMC Medicine  (2015) 13:72 Page 8 of 11A recent study by Uher et al. [132] suggests the available
opportunities. The authors found that individuals with
high baseline levels of systemic inflammation exhibited
increased depression recovery under nortriptyline, while
low inflammation levels were associated with superior
depression improvement under escitalopram, supporting
earlier work on the topic [133]. These results are espe-
cially interesting considering that inflammation levels are
particularly elevated among depressed individuals with
somatic symptoms [28], specifically appetite and weight
gain [27]. If patients with high and low baseline inflamma-
tion levels exhibit different symptoms, it should be
possible to select study participants who will respond to a
particular drug. Finding biological markers for specific
depressive symptoms will open new research vistas.
Conclusions
Depression symptoms are commonly added up to create
sum-scores that are assumed to reflect the severity of
a uniform underlying depressive disorder. This schema
discards data about specific symptoms, treating all as
equivalent and interchangeable indicators of MDD. It also
fosters asking simplistic questions such as ‘what causes
depression?’ or ‘what treatment is best for depression?’
Analyzing specific symptoms and their causal associations
is an initial step towards personalized treatment of depres-
sion that recognizes the heterogeneity of MDD. This is
certainly more complicated than the study of sum-scores,
but well worth the effort. As John Tukey [134] pointed out,
“Clarity in the large comes from clarity in the medium scale;
clarity in the medium scale comes from clarity in the small.
Clarity always comes with difficulty” (p. 88).
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